A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015

OBJECTIVES: High-cost antivascular endothelial growth factor (anti-VEGF) medicines for eye disorders challenge ophthalmologists and policymakers to provide fair access for patients while minimising costs. We describe the growth in the use and costs of these medicines and measure inequalities in acce...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollingworth, William, Jones, Tim, Reeves, Barnaby C, Peto, Tunde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665286/
https://www.ncbi.nlm.nih.gov/pubmed/29061629
http://dx.doi.org/10.1136/bmjopen-2017-018289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665286/
https://www.ncbi.nlm.nih.gov/pubmed/29061629
http://dx.doi.org/10.1136/bmjopen-2017-018289

Ejemplares similares